Safety and Pharmacokinetics of Quizartinib Combination Therapy With Standard Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia: Results from Two Phase 1 Trials in Japan and China

Documenti analoghi

• Outcomes of Elderly Patients Admitted to the Intensive Care Unit for Newly Diagnosed Acute Myeloid Leukemia
  di: Guillaume Berton, et al.
  Pubblicazione: (2025)
• Tolerability and Outcomes With Serial Cycles of 28 Days of Venetoclax in Newly Diagnosed Patients With Acute Myeloid Leukemia
  di: Michael K. Jones, et al.
  Pubblicazione: (2026)
• Cladribine With Low‐Dose Cytarabine and Venetoclax Alternating With Azacitidine and Venetoclax for Newly Diagnosed Acute Myeloid Leukemia
  di: Tapan M. Kadia, et al.
  Pubblicazione: (2026)
• Impact of Reduction in Myeloid‐derived Suppressor Cells by Wilms’ Tumor 1‐targeted Dendritic Cell Vaccines on Clinical Outcomes in Acute Leukemia Patients
  di: Masahiro Ogasawara, et al.
  Pubblicazione: (2025)
• Extended Versus Standard Hypomethylating Agent Dosing in Combination With Venetoclax in Patients With Newly Diagnosed Acute Myeloid Leukemia
  di: Georgio Medawar, et al.
  Pubblicazione: (2026)